Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD

J Am Acad Child Adolesc Psychiatry. 2001 Aug;40(8):903-6. doi: 10.1097/00004583-200108000-00011.

Abstract

Proton magnetic resonance spectroscopy (1H-MRS) was used to examine glutamatergic (Glx) abnormalities in the caudate nucleus in pediatric obsessive-compulsive disorder (OCD), associated with severity of illness and response to acute (12 weeks) treatment with paroxetine. In this report, OCD symptoms improved markedly in an 8-year-old girl treated for 14 months with the selective serotonin reuptake inhibitor paroxetine (titrated from 10 to 40 mg/day). Paroxetine dose was then decreased in 10-mg decrements and discontinued without symptom recurrence. Serial 1H-MRS examinations were acquired before and after 12 weeks of paroxetine treatment (40 mg/day) and 3 months after medication discontinuation. A striking decrease in caudate Glx was observed after 12 weeks of treatment which persisted after medication discontinuation. These data provide further support for a reversible glutamatergically mediated dysfunction of the caudate nucleus in OCD that may serve as a pathophysiological and treatment response marker.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Brain Chemistry / drug effects
  • Caudate Nucleus / drug effects*
  • Child
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Glutamic Acid / drug effects
  • Glutamic Acid / metabolism*
  • Humans
  • Magnetic Resonance Spectroscopy
  • Obsessive-Compulsive Disorder / drug therapy*
  • Obsessive-Compulsive Disorder / metabolism
  • Paroxetine / administration & dosage
  • Paroxetine / therapeutic use*
  • Remission Induction
  • Selective Serotonin Reuptake Inhibitors / administration & dosage
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*

Substances

  • Serotonin Uptake Inhibitors
  • Glutamic Acid
  • Paroxetine